Special Report: Incannex Healthcare (ASX:IHL) says its hydroxychloroquine/cannabidiol combination drug IHL-675A is vastly outperforming CBD alone in fighting inflammation in … Read More
The post Inncanex’s anti-inflammatory and COVID-19 drug candidate showing promise in pre-clinical studies appeared first on Stockhead.
Barry Stroman was a reporter for Zerg Watch, before becoming the lead editor. Barry has previously worked for Wired, MacWorld, PCWorld, and VentureBeat covering countless stories concerning all things related to tech and science. Barry studied at NYU.